Study links fine particle air pollution to 28% increased breast cancer risk

A study presented this month at the European Society for Medical Oncology Congress in Madrid found something that previous research had missed: women exposed to fine particle air pollution both at home and at work face a substantially higher risk of breast cancer than those in cleaner environments. The finding matters because it expands what we thought we knew about how pollution harms us—and it comes with a concrete number that changes how we might measure the threat.

Researchers compared air pollution exposure in 2,419 women diagnosed with breast cancer to exposure in 2,984 women without the disease, tracking both groups from 1990 through 2011. What they discovered was a statistically significant link between long-term exposure to fine particulate matter—particles so small they're measured as PM2.5, meaning 2.5 micrometers or smaller—and breast cancer risk. For every 10 microgram-per-cubic-meter increase in PM2.5 exposure, breast cancer risk rose by 28 percent. To put that in perspective, that 10-microgram difference is roughly what you'd experience moving from a rural European area to an urban one. The study also found smaller but measurable increases in breast cancer risk from exposure to larger particles and nitrogen dioxide.

What makes this work distinct is that it measured pollution exposure in two places at once. Earlier studies had looked only at where women lived. By including workplace exposure, the researchers captured a more complete picture of how much pollution people actually breathe over years and decades. Béatrice Fervers, who heads the Prevention Cancer Environment Department at Léon Bérard Comprehensive Cancer Centre in France, noted that this dual accounting revealed an association that previous single-location studies had largely missed or minimized.

The mechanism appears to work through the lungs and bloodstream. Charles Swanton, a researcher at the Francis Crick Institute in London, explained that these microscopic particles can penetrate deep into lung tissue and cross into the bloodstream, where they travel to breast tissue and other organs. Once there, evidence suggests they can alter the physical structure of breast tissue itself. The concern is that these particles might trigger inflammation or create conditions where cells with existing mutations can expand and develop into tumors—a process Swanton has observed in lung cancer cases among non-smokers exposed to similar pollution.

The findings have already influenced policy. In October 2022, the European Commission proposed lowering the legal limit for PM2.5 from 25 micrograms per cubic meter to 10 by 2030. The medical oncology society pushed for something stricter: 5 micrograms per cubic meter, aligning with World Health Organization air quality guidance. That recommendation gained traction. In June 2023, the European Parliament's Environment, Public Health and Food Safety Committee adopted the 5-microgram standard. Three months later, in September, the full European Parliament voted to include this target in its report on revising EU air quality directives. The vote opens negotiations between the Parliament, the European Commission, and the EU Council to finalize the new rules.

Jean-Yves Blay, ESMO's director of public policy, framed the stakes broadly. The evidence linking PM2.5 to cancer is now both epidemiological—based on population studies like this one—and biological, grounded in how the particles actually move through the body. Reducing pollution to WHO levels matters not just for breast cancer but for multiple tumor types. He acknowledged that change takes time and that the work extends beyond Europe, where pollution levels vary dramatically by region and country. But the direction, he suggested, is finally shifting toward what the science demands.